Introduction
Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related deaths worldwide [1] . Due to the high rate of recurrence and metastasis, the overall survival (OS) in HCC patients remains unsatisfactory, and survival at 5 years ranges between 50 and 70% [2] . Therefore, a better understanding of the molecular basis of HCC is required to improve current treatment modalities and to help identify novel targets of HCC.
The tripartite motif (TRIM) superfamily contains more than 60 types of TRIM proteins that are evolutionarily conserved. TRIM proteins are composed of 3 zinc-binding regions: RING finger, B-box, and coiled-coil domains [3] . TRIM14, previously known as KIAA0129, is an important member of the TRIM protein family. TRIM14 was first discovered in human immunodeficiency virus (HIV)-related human and simian non-Hodgkin's lymphomas [4, 5] . Previous studies have shown that TRIM14 served as a mitochondrial adaptor that facilitates retinoic acidinducible gene-I-like receptor-mediated innate immune responses against viral infections [6] . In addition, overexpression of TRIM14 in human HEK293T cells resulted in upregulation of several innate immunity-related genes that were involved in the activation of NF-κB and Wnt/β-catenin signaling pathways [7] . Recently, the involvement of TRIM14 in the host defense against viral infections was reported by 2 different groups. Chen et al. [8] revealed that TRIM14 inhibited degradation of cyclic GMP-AMP synthase (cGAS) that was mediated by selective autophagy receptor p62 to promote innate immune responses during herpes simplex virus (HSV)-1 infection. Moreover, Wang et al. [9] demonstrated that TRIM14 inhibited hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein. In conclusion, these 2 reports suggested that TRIM14 may be associated with activation of the NF-κB pathway and may play a role in tumorigenesis.
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Summary Background: Tripartite motif containing 14 (TRIM14) has been reported to play a critical role in tumor development. However, little is known about TRIM14 expression and its clinical significance in hepatocellular carcinoma (HCC). The aim of the present study was to investigate the expression and prognostic value of TRIM14 in patients with HCC. Materials and Methods: The mRNA and protein levels of TRIM14 in HCC were evaluated by quantitative real-time polymerase chain reaction, Western blot analysis, and immunohistochemistry. The association of TRIM14 expression with clinicopathological factors, overall survival (OS), and recurrence-free survival (RFS) was analyzed. Results: TRIM14 expression was significantly upregulated in HCC-related tissues. High TRIM14 expression correlated with C-reactive protein (p = 0.01), alanine aminotransferase (p = 0.02), tumor size (p = 0.005), lesion number (p = 0.023), vascular invasion (p = 0.041), tumor/node/metastasis (TNM) stage (p = 0.001), and Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.003). In addition, high TRIM14 expression was associated with poor OS and RFS (both p < 0.001). Cox regression analysis revealed that high TRIM14 expression was an independent prognostic factor for both OS (hazard ratio (HR) 1.657, 95% confidence interval (CI) 1.031-2.687; p = 0.018) and RFS (HR 2.297, 95% CI 1.184-2.312; p = 0.007). Conclusion: TRIM14 is a potential prognostic predictor for OS and RFS in patients with HCC.
Recently, 2 groups reported a different role of TRIM14 in cancer. First, Su et al. [10] showed that TRIM14 was significantly upregulated in squamous cells carcinoma of the tongue (TSCC) tissues, and that ectopic expression of TRIM14 promoted cell proliferation, metastasis, and angiogenesis by activating NF-κB signaling. These findings suggested an oncogenic role of TRIM14 in TSCC progression. However, Hai et al. [11] To date, the expression status and prognostic value of TRIM14 in patients with HCC has not yet been evaluated. Therefore, in the present study, mRNA and protein levels of TRIM14 were evaluated in patients with HCC by quantitative real-time polymerase chain reaction (qRT-PCR), Western blot analysis, and immunohistochemistry (IHC). The relationship between TRIM14 levels and various clinicopathological parameters was evaluated to assess the prognostic value of TRIM14 in HCC patients.
Materials and Methods
Patients and Specimens
A total of 166 paired paraffin-embedded tumor tissues and matched normal adjacent liver tissues were collected from patients with HCC at the Department of Pathology, Xianyang Central Hospital between January 2010 and December 2013. The inclusion criteria of the patients were: i) distinctive pathologic diagnosis of HCC; ii) primary and curative liver resection; and iii) complete set of clinicopathological and follow-up data. None of the patients had preoperative chemotherapy/radiotherapy or extrahepatic metastases. Tumor stages were determined by tumor/node/metastasis (TNM) classification according to the 2002 International Union Against Cancer guidelines. Barcelona Clinic Liver Cancer (BCLC) stage determined the treatment plan [12] . Each patient was classified based on the Child-Pugh score [13] . Tumor differentiation was graded according to the Edmondson-Steiner classification. Patients were followed-up until December 2016. Overall survival (OS) was defined as the interval between primary surgical treatment and death or the last follow-up date. Moreover, recurrence-free survival (RFS) was defined from the date of recurrence to the date of death or the last follow-up date. Clinical characteristics of both cases and controls are presented in table 1. For analysis of mRNA and protein expression, fresh tumor tissues and matched normal adjacent liver tissues from 10 HCC patients were obtained during surgery from the Department of Surgery, Xianyang Central Hospital between September 2016 and December 2016. The resected tissues were snap-frozen and stored at 80 ° C until they were used for qPCR and Western blot analysis. This study was approved by the Research Ethics Committee of Xianyang Central Hospital, P.R. China. The trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996. Written informed consent was obtained from all patients according to the committee's regulations.
Detection of TRIM14 by qRT-PCR
Total RNA was extracted from 10 pairs of fresh HCC and liver tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA concentration was assessed by measuring the absorbance at 260 nm using a NanoDrop spectrophotometer (ND-1000, Thermo Fisher Scientific, Waltham, MA, USA). A total of 2 μg RNA per sample was reverse transcribed using M-MLV reverse transcriptase (Life Technologies Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. The resulting cDNA was subjected to amplification of TRIM14 using the following primers: forward 5'-TACATTACA-GACGCCATTGGAC-3', reverse 5'-GGGCTGGTTTTCAACAAGGT-3'. The expression level of TRIM14 was normalized to that of the housekeeping gene β-actin using the comparative threshold cycle (2 ΔCt ) method.
Detection of TRIM14 by Western Blot Analysis
Total protein was extracted from 10 pairs of fresh HCC and liver tissues using Thermo Scientific RIPA lysis buffer (Thermo Fisher Scientific), and 50 μg of total protein extract was separated using 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Next, proteins were transferred onto a polyvinylidene fluoride membrane. The membrane was blocked with 5% skimmed milk in Tris-buffered saline containing Tween-20 (TBST) for 1 h and incubated overnight with a rabbit anti-TRIM14 antibody (1: 1,000, ab185349; Abcam, Cambridge, MA, USA) at 4 ° C. Membranes were washed 3 times with TBST and incubated with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG antibody at room temperature for 1 h. Proteins were visualized by enhanced chemiluminescence (ECL), and images were taken using a BioImaging System (UVP Inc., Upland, CA, USA).
Detection of TRIM14 by IHC
To detect the expression of TRIM14, IHC was performed using the streptavidin peroxidase-conjugated method. Briefly, paraffin-embedded HCC specimens were cut into 5-μm sections, deparaffinized, and treated with 3% H 2 O 2 solution in methanol for 10 min at room temperature. To retrieve antigenicity, the slides were boiled in a microwave oven in citrate buffer solution (pH 6.5) for 20 min. Subsequently, sections were incubated in 5% anti-goat serum for 15 min at 37 ° C. After rinsing with phosphate-buffered saline (PBS), sections were incubated overnight at 4 ° C with anti-TRIM14 antibody (1: 1,000, ab185349; Abcam). Sections were washed and incubated with a secondary antibody for 30 min followed by incubation with the streptavidin-horseradish peroxidase complex. The staining was developed with diaminobenzidine tetrahydrochloride and counterstained with hematoxylin. As negative controls, the primary antibody was omitted and sections were incubated with PBS only.
The score for TRIM14 staining was calculated by evaluating the intensity of the staining and the proportion of positive tumor cells. Briefly, 5 fields were randomly selected, and 3 slides for each specimen were counted. The intensity of the staining was scored as follows: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The staining extent was scored from 0 to 3 based on the percentage of positive cells (0: 0%; 1: 1-10%; 2: 11-50%, 3: 50-80%, and 4: 81-100%). The final TRIM14 expression score was calculated as follows: staining intensity score × the percentage of positive cells score, ranging between 0 and 12. The IHC scores were classified as follows: '-' (IHC score 0), '+' (IHC score 1-4), '++' (IHC score 5-8), and '+++' (IHC score 9-12). For statistical analysis, the cohort of 166 HCC patients was divided into a low TRIM14 expression group (IHC score 4) and a high TRIM14 expression group (IHC score > 4).
Statistical Analysis
Statistical analysis was performed using SPSS software version 17.0 for Windows (IBM Corp., Armonk, NY, USA). Data was expressed as the mean ± standard deviation. The association between TRIM14 and the clinicopathological characteristics was analyzed by Pearson's chi-square (χ 2 ) test. Survival curves were created with the estimator of survival function. Differences between survival curves were analyzed using the log-rank test. Cox regression analysis in a forward stepwise method was used to evaluate the effect of multiple independent prognostic factors on survival outcome. p < 0.05 was considered statistically significant.
Results
TRIM14 Expression is Upregulated in HCC Tissues
First, we evaluated TRIM14 mRNA expression in 10 paired fresh tumor and matched adjacent normal liver tissues by qPCR. As shown in figure 1 A, TRIM14 mRNA expression was significantly upregulated in all tumor tissues compared to paired normal tissues (p = 0.003). Western blot analysis was used to examine TRIM14 protein levels in the 10 pairs of tissues. The data showed that the protein level of TRIM14 was increased in 9 out of 10 HCC tissues ( fig. 1 B) . To gain a better understanding of the clinicopathological significance of TRIM14 in HCC, we used IHC staining and evaluated TRIM14 expression in 166 paraffin-embedded paired HCC and liver tissues. As shown in figure 2 A, typical TRIM14 immunostaining was primarily found in the cytoplasm of tumor cells. In contrast, weak or negative TRIM14 staining was ob-served in adjacent normal liver tissues ( fig. 2 A) . High expression of TRIM14 (IHC score > 4) was observed in 102/166 (61.4%) HCC tissues. The representative images of different TRIM14 staining intensities are shown in figure 2 B.
Correlation between TRIM14 Expression and Clinicopathological Features
The association between TRIM14 expression and clinicopathological characteristics was evaluated in 166 patients with HCC. 
High TRIM14 Expression Correlated with Poor Prognosis in HCC Patients
Kaplan-Meier analysis was applied to investigate the relationship between TRIM14 expression and the clinical outcomes of HCC patients. As shown in figures 3 A and B, patients with high levels of TRIM14 expression were found to have a poor OS (logrank test, p < 0.001) ( fig. 3 A) and shorter RFS (log-rank test, p < 0.001) ( fig. 3 B) compared to patients with low levels of TRIM14 expression.
Furthermore, the prognostic value of TRIM14 expression for OS and RFS was analyzed using univariate and multivariate analy- 
Discussion
TRIM14 is an important member of the TRIM protein family, which promotes cell proliferation, tumor angiogenesis, growth, and invasion of tumor cells [7] . TRIM14 levels have been found to be upregulated in HIV-associated lymphomas in monkeys and in TSCC [4, 5, 10] , suggesting a role of TRIM14 in cancer development and progression. However, the expression status of TRIM14 in HCC and its relationship with clinicopathological factors has not been identified.
In the present study, we performed qPCR and Western blot analysis to examine the expression level of TRIM14 in 10 paired HCC and adjacent liver tissues. We found that TRIM14 expression, at both the mRNA and the protein level, was significantly upregulated in 9 out of 10 HCC tissues. Next, TRIM14 protein expression was evaluated by IHC staining in a large population of 166 paraffin-embedded paired HCC and liver tissues. We found that typical immunostaining of TRIM14 was primarily detected in the cytoplasm of tumor cells. High expression of TRIM14 was detected in 61.4% of HCC tissues. In contrast, normal liver tissues exhibited mostly negative expression of TRIM14. These findings suggested that upregulation of TRIM14 expression may be associated with tumorigenesis in HCC. In line with our results, Su et al. [10] recently reported that TRIM14 was markedly upregulated in TSCC cell lines as well as in clinical tissues.
The present study determined the correlation between TRIM14 expression, clinicopathological parameters, OS, and RFS in HCC patients. We found that TRIM14 levels were associated with ALT, preoperative CRP, tumor size, lesion number, tumor invasion, TNM stage, and BCLC stage. However, levels of TRIM14 did not correlate with age, sex, AFP, liver cirrhosis, etiology, Child-Pugh score, and tumor differentiation, indicating that TRIM14 may be a valuable biomarker for predicting tumor progression in patients with HCC. Previous studies suggested that TRIM14 was correlated with clinical stage and TNM classification in patients with TSCC [10] . Collectively, our findings suggest a potential association between the upregulation of TRIM14 and HCC progression.
The relevance of TRIM14 for OS in cancer has been found to be controversial. Su et al. [10] reported that in TSCC patients with higher TRIM14 expression OS is shorter. However, Hai et al. [11] reported that in NSCLC, high TRIM14 mRNA levels correlated with better survival outcome after surgery. In our study, high TRIM14 expression correlated with poor OS and shorter RFS. In addition, multivariate Cox regression analysis indicated that high TRIM14 expression in HCC was an independent prognostic factor for both OS and RFS. These results indicate that TRIM14 may be a potential prognostic predictor of OS and RFS in patients with HCC. Therefore, care should be taken at follow-up after surgical resection in HCC patients with high TRIM14 expression.
However, the biological role and the mechanisms of action of TRIM14 in HCC remain to be identified. Su et al. [10] showed that ectopic expression of TRIM14 promoted tumor cell proliferation, angiogenesis, and increased resistance to cisplatin-induced apoptosis of TSCC cells in vitro, and contributed to tumorigenicity of TSCC cells in vivo by activating the NF-κB signaling pathway. However, Hai et al. [11] found that silencing TRIM14 expression significantly increased cell proliferation and colony formation in vitro and enhanced tumor growth in NSCLC xenograft mouse models by inhibiting apoptotic/cell death pathways. These apparently contradictory results suggest that abnormal expression of TRIM14 in different types of tumors may affect different molecular signaling pathways, resulting in different outcome. In the current study, we demonstrated that high expression of TRIM14 in HCC was implicated in tumor progression; however, further studies are required to investigate the role and underlying mechanisms of action of TRIM14 in HCC.
In summary, the present study demonstrated, for the first time, that TRIM14 was upregulated in HCC, and that high levels of TRIM14 were correlated with an unfavorable survival outcome. In addition, high TRIM14 expression was identified as an independent prognostic factor for OS and RFS in HCC patients. Our findings indicate that TRIM14 is a potential clinical biomarker in the diagnosis or prediction of clinical outcomes in patients with HCC.
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